Ebixa indications extended

The licensed indications for Ebixa (memantine) have been extended to allow its use in the treatment of moderate to severe Alzheimer's dementia. Previously, Ebixa's uses were limited to the treatment of moderately severe to severe Alzheimer's dementia.

The extension to Ebixa's licence follows a meta-analysis of patients with moderate to severe Alzheimer's dementia from six phase III, placebo-controlled, 6-month studies which showed that memantine had a significantly favourable effect in preventing worsening of cognitive, global and functional domains.

Memantine is an NMDA receptor antagonist that modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.

View Ebixa drug record

Further Information: Lundbeck Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...